샘플 요청 목록

 카트 문의
시장보고서
상품코드
2018377

혈액제재 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 항혈전제 및 항응고제별, 용도별, 지역별, 부문별 예측(2026-2033년)

Blood Preparation Market Size, Share & Trends Analysis Report By Product (Whole Blood, Blood Components, Blood Derivatives), By Antithrombotic And Anticoagulants, By Application, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ￦ 9,059,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ￦ 10,582,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ￦ 13,627,000
카드담기
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

혈액제제 시장 요약

세계의 혈액제재 시장 규모는 2025년에 535억 6,000만 달러로 추정되며, 2033년까지 918억 8,000만 달러에 달할 것으로 예측됩니다.

2026년부터 2033년까지 CAGR 7.1%로 성장할 것으로 예상됩니다. 혈액 관련 질환 발생률 증가, 수혈 횟수 증가, 헌혈자 수 증가 등이 시장을 견인하는 주요 요인으로 작용하고 있습니다.

또한, 다양한 수술에서 혈액 및 그 성분의 광범위한 사용, 사고 건수 증가, 헌혈 횟수 증가도 조사 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 미국 적십자사에 따르면 미국에서는 약 680만 명이 헌혈을 하고 있으며, 연간 약 1,360만 단위의 적혈구 및 전혈이 수집되고 있습니다.

빈혈, 혈우병, 백혈병, 혈소판 감소증과 같은 혈액 관련 질환의 유병률 증가는 세계 혈액제제 시장 성장의 주요 촉진요인입니다. 세계보건기구(WHO)에 따르면, 빈혈은 전 세계적으로 약 16억 명이 앓고 있는 것으로 추정되며, 이로 인해 적혈구 농축액과 철분 보충제에 대한 수요가 증가하고 있습니다. 마찬가지로 혈우병은 전 세계적으로 약 40만 명이 앓고 있으며, 응고인자 등 혈장 유래 제제에 대한 정기적인 접근이 필요한 질환입니다. 또한, 건강지표평가연구소(IHME)가 발표한 보고서에 따르면, 2021년 세계 데이터에 따르면 여성의 31.2%가 빈혈을 앓고 있는 반면 남성은 17.5%에 불과해 여성의 빈혈 유병률은 해마다 증가하고 있습니다. 마찬가지로, 비정상적인 전혈구수치(CBC) 검사 결과는 종종 잠재적인 감염을 암시하는 경우가 많으며, 이로 인해 환자들 사이에서 진단에 대한 일관된 요구가 발생하고 있습니다.

파스 바이오사이언스(Parse Biosciences)가 단일 세포 RNA 시퀀싱 애플리케이션을 위해 채혈 직후 전혈 샘플을 안정화시키는 솔루션 'Evercode Whole Blood Fixation'을 출시했다고 12월 4일 밝혔습니다. 본 제품은 채취 현장에서 말초혈액 단핵구(PBMC)의 즉각적인 분리 및 특수한 처리가 필요 없어 검체 처리를 간소화합니다. 이번 개발로 분산되고 유연한 채혈 워크플로우가 가능해져, 특히 유전체 연구 및 중개 유전체학 분야에서 혈액 검체 전처리 분야의 혁신을 강화할 수 있게 되었습니다.

수혈은 빈혈, 외상, 수술, 암 치료 등 다양한 질환의 치료에 필수적입니다. 예를 들어, 백혈병 환자의 경우 혈액을 만드는 신체 기능이 손상되어 질병과 그 증상을 관리하기 위해 수혈이 필수적입니다. 또한, 만성질환의 유병률 증가와 헬스케어 기술의 발전도 제품 수요 확대에 더욱 기여하고 있습니다.

또한, 제혈법 관련 연구개발 활동이 활발해짐에 따라 조사 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2025년 12월 잠셰드푸르 당국은 조사 보고서 제출 후 MGM 메디컬 칼리지의 혈액은행에 혈액 검사에 ELISA 키트를 도입하도록 명령했습니다. 이 지침은 수혈의 안전을 보장하기 위해 혈액은행에서 표준화된 감염 검사 프로토콜의 중요성을 재확인하는 것입니다. 이번 사건은 상용 제품 출시는 아니지만, 혈액제제 및 스크리닝 시장에 영향을 미치는 강력한 규제 감독을 강조하고 있으며, 검증된 혈액 검사 키트와 컴플라이언스 중심의 검사실 업무에 대한 수요를 견인하고 있습니다. 또한, 전 세계적으로 새로운 혈액은행 센터가 개설되는 것은 시장에 충분한 기회를 가져다 줄 수 있습니다. 예를 들어, 2023년 3월 케냐 보건부는 이 지역에서 양질의 안전한 수혈 서비스에 대한 접근성을 개선하기 위해 위성 혈액은행 센터를 도입했습니다.

또한, 아펠레시스를 포함한 채혈 및 보존 기술의 혁신으로 혈장, 혈소판 등 특정 혈액 성분을 효율적으로 채취할 수 있는 능력이 향상되었습니다. 이는 혈장 유래 치료제와 같은 첨단 제제의 공급망을 뒷받침하고 있습니다. 또한, 새로운 기술의 도입과 제약 산업에서 혈장 사용의 증가는 예측 기간 동안 시장 성장에 더욱 기여할 것으로 예상됩니다. 예를 들어, 2021년 4월, EryPharm은 배양 적혈구를 대량으로 생산하여 수혈을 위한 새로운 혈액원을 창출하는 의료기기를 도입했습니다. 세계 각국 정부는 헌혈자에게 금전적 인센티브를 제공하는 등 헌혈자 수를 늘리기 위해 다양한 정책을 시행하고 있습니다. 예를 들어, 2021년 9월 미국 적십자사는 겸상적혈구증 환자의 건강 상태를 개선하기 위해 가능한 한 많은 헌혈자를 확보하기 위한 전국적인 노력을 시작했습니다. 이러한 요인도 향후 몇 년 동안 세계 시장의 성장을 촉진할 것으로 예상됩니다.

자주 묻는 질문

  • 혈액제제 시장 규모는 어떻게 예측되나요?
  • 혈액제제 시장 성장을 견인하는 주요 요인은 무엇인가요?
  • 빈혈의 유병률은 어떻게 되나요?
  • 혈우병 환자의 수는 얼마나 되나요?
  • 혈액제제 시장에서 헌혈자 수를 늘리기 위한 정책은 무엇인가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 혈액제재 시장 : 변수, 동향, 범위

제4장 혈액제재 시장 : 제품별 추정·동향 분석 사례

제5장 혈액제재 시장 : 항혈전제 및 항응고제별 추정·동향 분석

제6장 혈액제재 시장 : 용도별 추정·동향 분석

제7장 혈액제재 시장 : 지역별 추정·동향 분석

제8장 경쟁 구도

KSM 26.05.13

Blood Preparation Market Summary

The global blood preparation market size was estimated at USD 53.56 billion in 2025 and is anticipated to reach USD 91.88 billion by 2033, growing at a CAGR of 7.1% from 2026 to 2033. The growing incidence of blood-related disorders, the rising number of transfusion procedures, and the increasing number of donations are the major factors driving the market.

Moreover, extensive usage of blood and its components in several surgical procedures, increasing number of accidents, and growing donations are also expected to fuel the market growth over the study period. For instance, according to the American National Red Cross, in the U.S., approximately 6.8 million people donate blood, and about 13.6 million units of red blood cells and whole blood are collected annually in the U.S.

The increasing prevalence of blood-related disorders, such as anemia, hemophilia, leukemia, and thrombocytopenia, is a primary driver for the growth of the global blood preparation market. According to the World Health Organization (WHO), it is estimated that anemia affects nearly 1.6 billion people globally, increasing the demand for red blood cell concentrates and iron supplements. Similarly, hemophilia affects approximately 400,000 people worldwide, requiring regular access to plasma-derived products such as clotting factors. In addition, according to a report published by the Institute for Health Metrics and Evaluation (IHME), globally in 2021, 31.2% of women had anemia compared with 17,5% of men, keeping anemia prevalence in women rising over the years. Similarly, abnormal Complete Blood Count (CBC) test results often indicate underlying infections, thereby creating a consistent demand for diagnosis among patient.

On 4 December 2025, Parse Biosciences announced the launch of Evercode Whole Blood Fixation, a solution designed to stabilize whole blood samples immediately after collection for single-cell RNA sequencing applications. The product enables simplified sample handling by eliminating the need for immediate peripheral blood mononuclear cell (PBMC) isolation and specialized processing at collection sites. This development strengthens innovation within the blood sample preparation segment, particularly for genomics research and translational diagnostics, by enabling decentralized and more flexible blood collection workflows.

Transfusions are essential in the treatment of numerous conditions such as anemia, trauma, surgical procedures, and cancer treatments. For instance, in leukemia patients the body's factory that makes blood damaged, hence transfusion is essential to manage the disease and its symptoms. Moreover, the rising prevalence of chronic diseases and advancements in healthcare technologies have further contributed to the growing demand for products.

In addition, increasing research and development activities on preparation methods is anticipated to propel the market growth during the review period. For instance, in December 2025, authorities in Jamshedpur ordered MGM Medical College's blood bank to implement ELISA kits for blood screening following the submission of a probe report. The directive reinforces the importance of standardized infectious disease screening protocols in blood banks to ensure transfusion safety. Although not a commercial product launch, the incident highlights the strong regulatory oversight influencing the blood preparation and screening market, driving demand for validated blood testing kits and compliance-focused laboratory practices. Furthermore, launch of new blood bank centers across the globe are likely to offer ample opportunities for the market. For instance, in March 2023, Kenya's Ministry of Health, introduced a satellite blood bank center for improving access to quality and safe transfusion services in the region.

Furthermore, innovations in blood collection and storage technology, including apheresis, have enhanced the ability to efficiently collect specific blood components such as plasma and platelets. This supports the supply chain for advanced preparations such as plasma-derived therapies. In addition, introduction of novel technologies along with the increasing usage of plasma in the pharmaceutical industry is further projected to contribute to market growth over the forecast period. For instance, in April 2021, EryPharm introduced a medical device to manufacture cultured red blood cells in large quantities and create new blood sources for transfusions. Various governments across the globe are focusing on increasing the number of donations by applying reimbursement policies, such as monetary incentives for donors. For instance, in September 2021, The American Red Cross introduced a national initiative to reach a maximum number of donors to improve health outcomes in patients with sickle cell disease. This factor is also expected to augment the growth of the global market over the next few years.

Global Blood Preparation Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood preparation market report based on product, antithrombotic & anticoagulants, application, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Whole Blood
    • Red Cells
    • Granulocytes
    • Plasma
    • Platelets
  • Blood Components
    • Whole Blood Components
    • Packed Red Cells
    • Leukocyte Reduced Red Blood Cells
    • Frozen Plasma
    • Platelet Concentrate
    • Cryoprecipitate
  • Blood Derivatives
  • Antithrombotic and Anticoagulants Outlook (Revenue, USD Million, 2021 - 2033)
  • Platelet Aggregation Inhibitors
    • Glycoprotein Inhibitors
    • COX Inhibitors
    • ADP Antagonists
    • Others
  • Fibrinolytics
    • Tissue Plasminogen Activator (tPA)
    • Streptokinase
    • Urokinase
  • Anticoagulants
    • Heparins
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin
    • Vitamin K Antagonists
    • Direct Thrombin Inhibitors
    • Direct Factor Xa Inhibitors
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Thrombocytosis
  • Pulmonary Embolism
  • Renal Impairment
  • Angina Blood Vessel Complications
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Anti-thrombotic & Anticoagulants
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Anti-thrombotic & Anticoagulants Outlook
    • 2.2.3. Application Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blood Preparation Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing incidence of blood-related disorders
      • 3.2.1.2. Rising number of transfusion procedures, and increasing donations
      • 3.2.1.3. Increasing research and development activities on preparation methods
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk of Transfusion-Related Complication
      • 3.2.2.2. Limited Awareness and Accessibility
  • 3.3. Blood Preparation Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Blood Preparation Market: Sample Estimates & Trend Analysis

  • 4.1. Sample Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Blood Preparation Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Whole Blood
    • 4.5.1. Whole Blood Market, 2021 - 2033 (USD Million)
    • 4.5.2. Red Cells
      • 4.5.2.1. Red Cells Market, 2021 - 2033 (USD Million)
    • 4.5.3. Granulocytes
      • 4.5.3.1. Granulocytes Market, 2021 - 2033 (USD Million)
    • 4.5.4. Plasma
      • 4.5.4.1. Plasma Market, 2021 - 2033 (USD Million)
    • 4.5.5. Platelets
      • 4.5.5.1. Platelets Market, 2021 - 2033 (USD Million)
  • 4.6. Blood Components
    • 4.6.1. Whole Blood Components
      • 4.6.1.1. Whole Blood Components Market, 2021 - 2033 (USD Million)
    • 4.6.2. Packed Red Cells
      • 4.6.2.1. Packed Red Cells Market, 2021 - 2033 (USD Million)
    • 4.6.3. Leukocyte Reduced Red Blood Cells
      • 4.6.3.1. Leukocyte Reduced Red Blood Cells Market, 2021 - 2033 (USD Million)
    • 4.6.4. Frozen Plasma
      • 4.6.4.1. Frozen Plasma Market, 2021 - 2033 (USD Million)
    • 4.6.5. Platelet Concentrate
      • 4.6.5.1. Whole Blood Components Market, 2021 - 2033 (USD Million)
    • 4.6.6. Cryoprecipitate
      • 4.6.6.1. Cryoprecipitate Market, 2021 - 2033 (USD Million)
  • 4.7. Blood Derivatives
    • 4.7.1. Blood Derivatives Market, 2021 - 2033 (USD Million)

Chapter 5. Blood Preparation Market: Anti-Thrombotic and Anticoagulants Estimates & Trend Analysis

  • 5.1. Anti-Thrombotic and Anticoagulants Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Blood Preparation Market by Anti-Thrombotic and Anticoagulants Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Platelet Aggregation Inhibitors
    • 5.5.1. Platelets Aggregation Inhibitors Market, 2021 - 2033 (USD Million)
    • 5.5.2. Glycoprotein Inhibitors
      • 5.5.2.1. Glycoprotein Inhibitors Market, 2021 - 2033 (USD Million)
    • 5.5.3. COX Inhibitors
      • 5.5.3.1. COX Inhibitors Market, 2021 - 2033 (USD Million)
    • 5.5.4. ADP Antagonist
      • 5.5.4.1. ADP Antagonist Market, 2021 - 2033 (USD Million)
    • 5.5.5. Others
      • 5.5.5.1. Others Market, 2021 - 2033 (USD Million)
  • 5.6. Fibrinolytics
    • 5.6.1. Fibrinolytics Market, 2021 - 2033 (USD Million)
    • 5.6.2. Tissue Plasminogen Activator
      • 5.6.2.1. Others Market, 2021 - 2033 (USD Million)
    • 5.6.3. Streptokinase
      • 5.6.3.1. Streptokinase Market, 2021 - 2033 (USD Million)
    • 5.6.4. Urokinase
      • 5.6.4.1. Urokinase Market, 2021 - 2033 (USD Million)
  • 5.7. Anticoagulants
    • 5.7.1. Anticoagulants Market, 2021 - 2033 (USD Million)
    • 5.7.2. Heparins
      • 5.7.2.1. Heparins Market, 2021 - 2033 (USD Million)
      • 5.7.2.2. Unfractionated heparin
        • 5.7.2.2.1. Unfractionated heparin Market, 2021 - 2033 (USD Million)
      • 5.7.2.3. Low Molecular Weight heparin
        • 5.7.2.3.1. Low Molecular Weight Heparin Market, 2021 - 2033 (USD Million)
      • 5.7.2.4. Ultra-Low Molecular Weight Heparin
        • 5.7.2.4.1. Ultra-Low Molecular Weight Heparin Market, 2021 - 2033 (USD Million)
    • 5.7.3. Vitamin K Antagonist
      • 5.7.3.1. Vitamin K Antagonist Market, 2021 - 2033 (USD Million)
    • 5.7.4. Direct Thrombin Inhibitors
      • 5.7.4.1. Direct Thrombin Inhibitors Market, 2021 - 2033 (USD Million)
    • 5.7.5. Direct factor Xa inhibitors
      • 5.7.5.1. Direct factor Xa Inhibitors Market, 2021 - 2033 (USD Million)

Chapter 6. Blood Preparation Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Blood Preparation Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Thrombocytosis
    • 6.5.1. Thrombocytosis Market, 2021 - 2033 (USD Million)
  • 6.6. Pulmonary Embolism
    • 6.6.1. Pulmonary Embolism Market, 2021 - 2033 (USD Million)
  • 6.7. Renal Impairment
    • 6.7.1. Renal Impairment Market, 2021 - 2033 (USD Million)
  • 6.8. Angina Blood Vessel Complication
    • 6.8.1. Angina Blood Vessel Complication Market, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Other Application Market, 2021 - 2033 (USD Million)

Chapter 7. Blood Preparation Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2025
    • 8.3.4. Pfizer, Inc
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Bristol-Myers Squibb Company
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Leo Pharma A/S
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Sanofi
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Xiamen Hisunny Chemical Co., LTD
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. AstraZeneca plc
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Baxter International Inc
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Portola Pharmaceuticals, Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. GlaxoSmithKline PLC
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Shandong East Chemical Industry Co.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Celgene Corp.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기